Represents the profit sharing ration between the company and the counterparty under the agreement.

No definition available.

Name:	ptgx_CollaborativeAgreementProfitSharePercentage
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of upfront payment based on the agreement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeAgreementUpfrontPayment
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount received from a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementEligibleAmountReceived
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the milestone additional payment eligible to receive from a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementMilestoneAdditionalPaymentEligibleToReceive
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the milestone payment amount eligible to receive from a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementMilestonePaymentEligibleToReceive
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of milestone payments allocated to performance obligations.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementMilestonePaymentsAllocatedToPerformanceObligations
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment previously due eliminated.

+ References

No definition available.

+ Details

Name:	ptgx_EliminationOfPreviouslyDueMilestonePayment
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of increase in milestone payment receivable during the period.

+ References

No definition available.

+ Details

Name:	ptgx_IncreaseInMilestonePayment
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of milestone payment receivable.

+ References

No definition available.

+ Details

Name:	ptgx_MilestonePaymentReceivable
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of royalties on net sales.

+ References

No definition available.

+ Details

Name:	ptgx_PercentageOfRoyaltiesOnNetSalesPercent
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentages on net product sales.

+ References

No definition available.

+ Details

Name:	ptgx_PercentagesRoyaltiesOnNetProductSales
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash inflow from milestone payments under the license and collaboration agreement.

+ References

No definition available.

+ Details

Name:	ptgx_ProceedsFromMilestonePayments
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents upcoming potential development and regulatory milestone payments receivable.

+ References

No definition available.

+ Details

Name:	ptgx_UpcomingPotentialDevelopmentAndRegulatoryMilestonesPayments
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents upcoming potential development milestones payment.

+ References

No definition available.

+ Details

Name:	ptgx_UpcomingPotentialDevelopmentMilestonesPayment
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList
Namespace Prefix:	us-gaap_
Data Type:	enum2:enumerationSetItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseThreeClinicalTrialForAnyIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_FoodAndDrugAdministrationApprovalOfNewDrugApplicationInAnyIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_AcceptanceOfNewDrugApplicationFiledByFoodAndDrugAdministrationApprovalForSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_FoodAndDrugAdministrationApprovalOfNewDrugApplicationForSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_AcceptanceOfNewDrugApplicationFiledByFoodAndDrugAdministrationApprovalForAnyIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInFirstPhase3ClinicalTrialForSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ptgx_TakedaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ptgx_DevelopmentServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseThreeClinicalTrialForRusfertideInPvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_FoodAndDrugAdministrationApprovalOfNewDrugApplicationForRusfertideInPvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptgx_ExerciseOfFullOptOutRightMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_FirstRegulatoryApprovalInThreeEuropeanCountriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_FirstRegulatoryApprovalInJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptgx_ExerciseOfFullOptOutRightDuringInitialOptOutPeriodMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements (Details) - USD ($) $ in Thousands	1 Months Ended					3 Months Ended			6 Months Ended		102 Months Ended
	Nov. 30, 2024	Oct. 31, 2024	Apr. 30, 2024	Mar. 31, 2024	Jan. 31, 2024	Jun. 30, 2025	Dec. 31, 2024	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Mar. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaboration revenue						$ 5,546		$ 4,167	$ 33,867	$ 259,120
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]						License And Service		License And Service	License And Service	License And Service
Contract asset						$ 23,363			$ 23,363		$ 23,363
Recognized revenue from deferred revenue contract liability						5,000		$ 4,200	$ 10,500	$ 0
Contract with customer, deferred revenue contract liability								40,900		40,900
Phase 3 clinical trial for a second-generation compound for any indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Increase in milestone payment	$ 50,000
Milestone payment receivable	165,000	$ 115,000
Janssen \| Restated Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalties on net product sales									6.00%
Janssen \| Restated Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalties on net product sales									10.00%
Janssen \| License and collaboration agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaboration revenue							$ 165,000
Proceeds from Milestone Payments											337,500
Janssen \| License and collaboration agreement \| Food And Drug administration approval of New Drug Application in any indication.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development milestones						50,000			$ 50,000		50,000
Janssen \| License and collaboration agreement \| Acceptance of New Drug Application filed by Food And Drug Administration approval for second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development milestones						25,000			25,000		25,000
Janssen \| License and collaboration agreement \| Food And Drug Administration approval of New Drug Application for second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development milestones						45,000			45,000		45,000
Janssen \| License and collaboration agreement \| Dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development milestones						35,000			35,000		35,000
Janssen \| License and collaboration agreement \| Acceptance of New Drug Application filed by Food And Drug Administration approval for any indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Elimination of previously due milestone payment	35,000
Janssen \| License and collaboration agreement \| Phase 3 clinical trial for a second-generation compound for any indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development milestones						50,000			50,000		50,000
Janssen \| License and collaboration agreement \| Dosing of third patient in first phase3 clinical trial for second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Elimination of previously due milestone payment	$ 15,000
Takeda Pharmaceuticals \| License And Service
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Profit (loss) share on U.S. profits and losses			50.00%
Takeda Pharmaceuticals \| Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment					$ 45,900
Revenue recognized										5,000
Takeda Pharmaceuticals \| License and collaboration agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment			$ 300,000
Final transaction price					300,000							$ 325,000
Revenue recognized				$ 254,100		5,500		$ 4,200	33,900	$ 259,100
Contract asset						23,400			23,400		23,400
Takeda Pharmaceuticals \| License and collaboration agreement \| Phase Three Clinical Trial For Rusfertide In PV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaboration revenue						500			23,400
Upcoming potential development and regulatory milestone payments receivable						25,000			25,000		25,000	25,000
Takeda Pharmaceuticals \| License and collaboration agreement \| Food And Drug Administration Approval Of New Drug Application For Rusfertide In PV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development and regulatory milestone payments receivable					50,000
Takeda Pharmaceuticals \| License and collaboration agreement \| Food And Drug Administration Approval Of New Drug Application For Rusfertide In PV [Member] \| Exercise of Full Opt-out Right [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development and regulatory milestone payments receivable					75,000
Takeda Pharmaceuticals \| License and collaboration agreement \| First regulatory approval in three European countries
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development and regulatory milestone payments receivable					15,000
Takeda Pharmaceuticals \| License and collaboration agreement \| First regulatory approval in japan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upcoming potential development and regulatory milestone payments receivable					$ 10,000
Takeda Pharmaceuticals \| License and collaboration agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalties on ex-U.S. net sales			10.00%		14.00%
Takeda Pharmaceuticals \| License and collaboration agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, milestone payment, eligible to receive			$ 305,000
Additional payment eligible to receive from a collaborative arrangement					$ 200,000
Percentage of royalties on ex-U.S. net sales			17.00%		29.00%
Takeda Pharmaceuticals \| License and collaboration agreement \| Maximum \| Exercise of Full Opt-out Right [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, milestone payment, eligible to receive					$ 975,000
Takeda Pharmaceuticals \| License and collaboration agreement \| Maximum \| Exercise of Full Opt-out Right During The Initial Opt-out Period (Member)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, milestone payment, eligible to receive					200,000
Takeda Pharmaceuticals \| License and collaboration agreement \| License and Maintenance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment					$ 254,100
Milestone payments allocated to performance obligations												21,300
Takeda Pharmaceuticals \| License and collaboration agreement \| Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Final transaction price						1,600			1,600		$ 1,600
License and collaboration revenue						$ 5,000			$ 10,500
Milestone payments allocated to performance obligations												$ 3,700